XORTX Therapeutics (XRTX) FCF Margin (2022 - 2023)

XORTX Therapeutics (XRTX) posted FCF Margin of 0.13% for Q2 2023, down 34.11% on a QoQ basis from 0.2% in Q1 2023.

XORTX Therapeutics (XRTX) FCF Margin (2022 - 2023) Analysis & Trends

XORTX Therapeutics' FCF Margin history runs 2 years deep, the most recent figure standing at 0.13% for Q2 2023.

Quarterly FCF Margin changed N/A year-over-year to 0.13% in Q2 2023, while the trailing twelve-month figure through Dec 2023 was 0.21% (up 20949.0% YoY) and the FY2022 annual result came in at 465.23%, changed N/A from the prior year.
FCF Margin was 0.13% for Q2 2023 at XORTX Therapeutics, down from 0.2% in the prior quarter.
Across five years, FCF Margin topped out at 103.71% in Q3 2022 and bottomed at 645.35% in Q4 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	10.45%
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	43.35%
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	23.53%
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	XORTX Therapeutics	2.91 Bn	2.91 Bn	-	-

Historic Data

Download Data

Date	Value
Jun 30, 2023	0.13%
Mar 31, 2023	0.20%
Dec 31, 2022	-645.35%
Sep 30, 2022	103.71%